<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035641</url>
  </required_header>
  <id_info>
    <org_study_id>AND017-MN-201</org_study_id>
    <nct_id>NCT05035641</nct_id>
  </id_info>
  <brief_title>A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients</brief_title>
  <official_title>A Pilot Phase II Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral AND017 to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kind Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kind Pharmaceuticals LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot phase 2, multicenter, randomized, parallel-group, double-blind,&#xD;
      placebo-controlled, dose-ranging, safety and efficacy study of oral AND017 to treat anemia in&#xD;
      non-dialysis-dependent chronic kidney disease patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluations</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing</measure>
    <time_frame>Up to 5 weeks after dosing</time_frame>
    <description>Calculate the slope of a linear regression for each patient using all hemoglobin data collected during the Fixed-Dose Period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hb response to treatment during Period 1</measure>
    <time_frame>Up to 5 weeks after dosing</time_frame>
    <description>Cumulative percentage of patients with Hb ≥10.0 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responder patients</measure>
    <time_frame>Up to 13 weeks after dosing</time_frame>
    <description>Responder is defined as a hemoglobin ≥10.0 g/dL and an increase in hemoglobin by ≥1.0 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL</measure>
    <time_frame>Up to 13 weeks after dosing</time_frame>
    <description>Percentage of visits at which patients maintain hemoglobin between 10.0-11.0 g/dL after achieving hemoglobin ≥10.0 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hb</measure>
    <time_frame>Up to 13 weeks after dosing</time_frame>
    <description>Change from baseline in Hb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels from baseline to the mean of weeks 10-13</measure>
    <time_frame>Baseline and at Week 10, 11, 12, 13, and 14</time_frame>
    <description>Change in hemoglobin levels from baseline to the mean of weeks 10-13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit</measure>
    <time_frame>Up to 13 weeks after dosing</time_frame>
    <description>Percentage of patients who maintain hemoglobin between 10.0-11.0g/dL at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hb levels at weeks 6-14 including the average of weeks 10-13</measure>
    <time_frame>Up to 13 weeks after dosing</time_frame>
    <description>Mean Hb levels at weeks 6-14 including the average of weeks 10-13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of lack of response over the entire treatment period</measure>
    <time_frame>Up to13 weeks after dosing</time_frame>
    <description>Hb level &lt; 10.0 g/dL and an increase in hemoglobin from baseline of &lt; 1 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in the levels of PD indicator - EPO</measure>
    <time_frame>Baseline and at Week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess changes in the levels of EPO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in the levels of PD indicator - hepcidin</measure>
    <time_frame>Baseline and at Week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess changes in the levels of hepcidin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess iron utilization parameter during treatment - transferrin level</measure>
    <time_frame>Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess transferrin level during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess iron utilization parameter during treatment - total iron-binding capacity (TIBC)</measure>
    <time_frame>Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess TIBC level during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess iron utilization parameter during treatment - transferrin saturation (TSAT)</measure>
    <time_frame>Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess TSAT level during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess iron utilization parameters during treatment - ferritin</measure>
    <time_frame>Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess ferritin level during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess iron utilization parameters during treatment - serum iron</measure>
    <time_frame>Baseline and at Week 3, 6, 9, 12, 14, and 28 days after the last dose</time_frame>
    <description>To assess serum iron level during treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Renal Anemia</condition>
  <arm_group>
    <arm_group_label>AND017 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AND017 will be administrated orally at dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AND017 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AND017 will be administrated orally at dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AND017 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AND017 will be administrated orally at dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administrated orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AND017</intervention_name>
    <description>Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2</description>
    <arm_group_label>AND017 Dose A</arm_group_label>
    <arm_group_label>AND017 Dose B</arm_group_label>
    <arm_group_label>AND017 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally, 3 times per week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Important Inclusion Criteria:&#xD;
&#xD;
          1. Non-dialysis-dependent renal anemia patients who are naïve to ESA and&#xD;
             prolyl-hydroxylase inhibitors.&#xD;
&#xD;
          2. Baseline Hb level ≥ 8 g/dL and &lt;10.0 g/dL.&#xD;
&#xD;
          3. No iron deficiency and no other cause for anemia other than CKD.&#xD;
&#xD;
          4. TSAT ≥ 20% and ferritin ≥ 100 ng/mL at screening test&#xD;
&#xD;
          5. Serum folate and vitamin B12 ≥ lower limit of normal at screening test&#xD;
&#xD;
        Important Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent retinal neovascular lesions requiring treatment including proliferative&#xD;
             diabetic retinopathy, exudative age-related macular degeneration, retinal vein&#xD;
             occlusion, macular edema, etc.&#xD;
&#xD;
          2. Concurrent autoimmune disease with inflammatory symptoms that is possibly the&#xD;
             principal cause of anemia.&#xD;
&#xD;
          3. History of gastric/intestinal resection considered influential on the absorption of&#xD;
             drugs in the gastrointestinal tract or concurrent gastroparesis.&#xD;
&#xD;
          4. Clinically significant bleeding (eg, requiring transfusion or drop in Hb of ≥ 2g/dL)&#xD;
             within 4 weeks of first dose; no bleeding diathesis or risk of bleeding that has not&#xD;
             been medically or surgically corrected at least 4 weeks prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          5. Uncontrolled hypertension (more than one-third of identifiable diastolic blood&#xD;
             pressure values &gt;90 mmHg within 16 weeks prior to and including the screening&#xD;
             assessment).&#xD;
&#xD;
          6. Concurrent congestive heart failure (New York Heart Association [NYHA] Class III or&#xD;
             higher).&#xD;
&#xD;
          7. History of stroke, transient ischemic attack, myocardial infarction, thromboembolic&#xD;
             event, pulmonary embolism, or lung infarction within 24 weeks before the screening&#xD;
             assessment.&#xD;
&#xD;
          8. Concurrent anemia due to another cause other than renal anemia&#xD;
&#xD;
          9. Known hemosiderosis, hemochromatosis or hyper-coagulable condition&#xD;
&#xD;
         10. Patients that have major surgery planned during the study period.&#xD;
&#xD;
         11. Having undergone blood transfusion and/or a surgical procedure within 8 weeks before&#xD;
             the screening assessment.&#xD;
&#xD;
         12. Having undergone a kidney transplantation.&#xD;
&#xD;
         13. History of a seizure disorder or any occurrence of seizures in the past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusha Zhu, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kind Pharmaceuticals LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Zhu</last_name>
    <phone>617-780-8445</phone>
    <email>qzhu@kindpharmaceutical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elite Research Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wafaa Hammoud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Yancy-Spurgeon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Zuo</last_name>
    </contact>
    <investigator>
      <last_name>Li Zuo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

